TTRXHealthcare · Biotechnology

TTRX Stock Forecast: Turn Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$13

−5.16% on the day

The 1 Wall Street analysts covering Turn Therapeutics, Inc. hold a median 12-month price target of $26 — +104.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$385.4M

Ticker Nerd rank

16 / 100

Median analyst target

$26

Analysts covering

Revenue$0.0

Operating income−$1.6M

Net income−$5.8M

Free cash flow−$929K

Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+26.0%

+24.2%

YTD

+222.1%

From high

−7.7%

From low

+368.3%

$14

Range since 8 Oct 2025, adjusted closes · the dot is the last close

Ticker Nerd rank

TTRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Turn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value

Accruals

Size

Revisions

Quality

Growth

Momentum

Issuance

Volatility

Value (83): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TTRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TTRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 8 Oct 2025Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $26Median $26High $26

The green dot is the last close — the median target sits +104.9% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
24 Mar 2026	D. Boral Capital	Maintains	Buy	$8.00
24 Mar 2026	D. Boral Capital	Maintains	Buy	—
20 Jan 2026	D. Boral Capital	Maintains	Buy	—
29 Dec 2025	D. Boral Capital	Initiates	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TTRX appears on the weeks it earns a place.

Performance

TTRX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

TTRX vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TTRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Turn Therapeutics, Inc. (TTRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −110.5×
Price / sales: —
Price / book: 570.9×
EV / EBITDA: −43.9×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −686.3%
Return on assets: −50.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Turn Therapeutics, Inc. (TTRX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Turn Therapeutics, Inc. has a market value of $385.4M and an enterprise value of $373.8M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$8.4M.
Free cash flow in the twelve months to 30 June 2026: −$4.5M.
Shares outstanding: 29.8M.
Trailing P/E: −110.5×; forward P/E: −87.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Turn Therapeutics, Inc. employs 2 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

TTRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
TTRXTurn Therapeutics, Inc.	$385.4M	16
ENTAEnanta Pharmaceuticals, Inc.	$373.9M	86
INDPIndaptus Therapeutics, Inc.	$369.1M	23
EVMNEvommune, Inc.	$379.6M	10
PRLDPrelude Therapeutics, Inc.	$365.6M	95
RCKTRocket Pharmaceuticals, Inc.	$362.5M	55
CMPXCompass Therapeutics, Inc.	$360.2M	32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Turn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TTRX news & analysis

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Business Wire · 10 Sept 2026positive

Turn Therapeutics Inc. (Nasdaq: TTRX) announced that CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET, with the presentation providing a detailed look at the company's work.

Why it matters — TTRX watchers would be interested because the company's leadership presentation at a Stifel investor forum offers visibility for its targeted therapies for inflammatory skin diseases at a major investment conference.

Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D.

Business Wire · 9 Sept 2026positive

Turn Therapeutics announced the appointment of Robert R. Redfield, M.D., former CDC Director, as Chief Scientific Officer. Dr. Redfield brings over four decades of experience in immunology, microbiology, infectious disease, clinical research, and public health to the clinical-stage biotech company.

Why it matters — A TTRX watcher would care because adding a former CDC Director with extensive infectious-disease expertise could strengthen the company's scientific leadership as it develops non-systemic therapies for skin diseases.

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Business Wire · 20 Aug 2026positive

Turn Therapeutics announced the publication of new peer-reviewed research in the journal Life providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several key inflammatory signals and drivers of itch associated with inflammatory skin disease.

Why it matters — The peer-reviewed in-vivo findings add scientific validation for GX-03, Turn Therapeutics' lead investigational therapy for inflammatory skin conditions.

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Business Wire · 12 Aug 2026positive

Turn Therapeutics provided corporate updates and reported financial results for the three and six months ended June 30, 2026. The company's review of interim GX-03 Phase 2 data indicated activity across a broader range of conditions, with management describing the second quarter as one of the most productive in its history.

Why it matters — A Turn Therapeutics watcher would care because the interim GX-03 Phase 2 data update and quarterly financial report provide an early look at the clinical progress and financial position of its lead skin-disease therapy candidate.

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Business Wire · 28 July 2026positive

Turn Therapeutics announced that CEO Bradley Burnam and members of the management team will ring the Nasdaq Closing Bell on August 10, 2026, at Nasdaq's invitation to mark the company's progress to date.

Why it matters — The Nasdaq's invitation for Turn Therapeutics to ring the closing bell signals recognition of the company's achievements and milestones as a publicly traded clinical-stage biotechnology firm.

FAQ

Frequently asked questions about TTRX stock

What is the TTRX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Turn Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $26 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TTRX stock a buy right now?

Of the 1 analysts covering Turn Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Turn Therapeutics, Inc. 16 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TTRX?

As at 12 Sept 2026, Turn Therapeutics, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (83 of 100).

Will TTRX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +104.9% from the last close, and Ticker Nerd's factor model ranks Turn Therapeutics, Inc. 16 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TTRX stock forecast for 2030?

No analyst covering Turn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TTRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $26 to $26 over the next 12 months.

What does Turn Therapeutics, Inc. do?

Turn Therapeutics Inc. is a clinical-stage biotechnology and medical device company focused on developing targeted therapies for dermatology, wound care, and infectious disease.

What is the latest news on TTRX?

The most recent item we track (Business Wire, 10 Sept 2026): "Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum". Turn Therapeutics Inc. (Nasdaq: TTRX) announced that CEO Bradley Burnam and Executive Clinical and Regulatory Lead Stephen M. Hahn, M.D., will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET, with the presentation providing a detailed look at the company's work.

Company

About Turn Therapeutics, Inc.

Turn Therapeutics Inc. is a clinical-stage biotechnology and medical device company focused on developing targeted therapies for dermatology, wound care, and infectious disease. The company’s product portfolio is built around its proprietary PermaFusion platform, which is designed to improve how active ingredients are delivered and perform in topical treatments. Its current programs include non-systemic therapies for inflammatory skin conditions such as atopic dermatitis, along with treatments for nail and wound-related disorders. Turn Therapeutics also maintains a portfolio of FDA-cleared medical devices and works across healthcare settings that address acute and chronic skin conditions, dermatoses, and infection control. Based in Westlake Village, California, the company operates at the intersection of pharmaceuticals and medical devices, supporting clinicians with localized treatment options designed to act directly at the site of disease.

CEO Mr. Bradley E. Burnam · 2 employees · United States · https://turntherapeutics.com